Literature DB >> 21183842

Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data.

Jacqueline E Tate1, Margaret M Cortese, Daniel C Payne, Aaron T Curns, Catherine Yen, Douglas H Esposito, Jennifer E Cortes, Benjamin A Lopman, Manish M Patel, Jon R Gentsch, Umesh D Parashar.   

Abstract

BACKGROUND: Rotavirus vaccine was recommended for routine use in US infants in 2006. Before the introduction of vaccine, rotavirus was the most common cause of severe gastroenteritis in children <5 years of age in the United States.
METHODS: We reviewed published data to summarize the US experience during the first 3 years of its rotavirus vaccination program.
RESULTS: Rotavirus seasons have been delayed and diminished in magnitude during the postvaccine era compared with the prevaccine era. Hospitalizations, emergency department visits, and outpatient visits due to gastroenteritis have declined dramatically in children < 5 years of age including in children age-ineligible to have received vaccine, suggesting indirect benefits of vaccination. Rotavirus vaccine has been widely accepted by pediatricians. Vaccine coverage is steadily increasing but remains lower than coverage levels of other routine infant immunizations.
CONCLUSIONS: The implementation of routine childhood immunization against rotavirus has rapidly and dramatically reduced the large health burden of rotavirus gastroenteritis in US children. Continued monitoring of rotavirus diarrhea is needed to determine if immunity wanes as vaccinated children get older and to better quantify the indirect benefits of vaccination. Ongoing surveillance will also enable monitoring of the long-term impact of vaccination on rotavirus epidemiology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21183842     DOI: 10.1097/INF.0b013e3181fefdc0

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  48 in total

Review 1.  Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

Review 2.  New insights into rotavirus vaccines.

Authors:  Chiara Mameli; Valentina Fabiano; Gian Vincenzo Zuccotti
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

3.  International society for disease surveillance conference 2011: building the future of public health surveillance.

Authors:  Daniel B Neill; Karl A Soetebier
Journal:  Emerg Health Threats J       Date:  2011-12-06

4.  Determining the effectiveness of the pentavalent rotavirus vaccine against rotavirus hospitalizations and emergency department visits using two study designs.

Authors:  Stephanie Donauer; Daniel C Payne; Kathryn M Edwards; Peter G Szilagyi; Richard W Hornung; Geoffrey A Weinberg; James Chappell; Caroline B Hall; Umesh D Parashar; Mary Allen Staat
Journal:  Vaccine       Date:  2013-04-12       Impact factor: 3.641

5.  Direct, indirect, total, and overall effectiveness of the rotavirus vaccines for the prevention of gastroenteritis hospitalizations in privately insured US children, 2007-2010.

Authors:  Catherine A Panozzo; Sylvia Becker-Dreps; Virginia Pate; David J Weber; Michele Jonsson Funk; Til Stürmer; M Alan Brookhart
Journal:  Am J Epidemiol       Date:  2014-02-26       Impact factor: 4.897

6.  Hospitalizations for intussusception before and after the reintroduction of rotavirus vaccine in the United States.

Authors:  Joseph S Zickafoose; Brian D Benneyworth; Meredith P Riebschleger; Claudia M Espinosa; Matthew M Davis
Journal:  Arch Pediatr Adolesc Med       Date:  2012-01-02

Review 7.  Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality From Diarrhea.

Authors:  Eleanor Burnett; Christine L Jonesteller; Jacqueline E Tate; Catherine Yen; Umesh D Parashar
Journal:  J Infect Dis       Date:  2017-06-01       Impact factor: 5.226

8.  Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011.

Authors:  Daniel C Payne; Julie A Boom; Mary Allen Staat; Kathryn M Edwards; Peter G Szilagyi; Eileen J Klein; Rangaraj Selvarangan; Parvin H Azimi; Christopher Harrison; Mary Moffatt; Samantha H Johnston; Leila C Sahni; Carol J Baker; Marcia A Rench; Stephanie Donauer; Monica McNeal; James Chappell; Geoffrey A Weinberg; Azadeh Tasslimi; Jacqueline E Tate; Mary Wikswo; Aaron T Curns; Iddrisu Sulemana; Slavica Mijatovic-Rustempasic; Mathew D Esona; Michael D Bowen; Jon R Gentsch; Umesh D Parashar
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

9.  Validation of the modified Vesikari score in children with gastroenteritis in 5 US emergency departments.

Authors:  David Schnadower; Phillip I Tarr; Marc H Gorelick; Karen O'Connell; Cindy G Roskind; Elizabeth C Powell; Jayashree Rao; Seema Bhatt; Stephen B Freedman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-10       Impact factor: 2.839

10.  Targeting pediatric versus elderly populations for norovirus vaccines: a model-based analysis of mass vaccination options.

Authors:  Molly K Steele; Justin V Remais; Manoj Gambhir; John W Glasser; Andreas Handel; Umesh D Parashar; Benjamin A Lopman
Journal:  Epidemics       Date:  2016-10-24       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.